Delivery systems for the treatment of degenerated intervertebral discs

Advanced Drug Delivery Reviews

Volumn 84, Issue , 2015, Pages 172-187

  Blanquer, S B G ^a,b   Grijpma, D W ^a,b,c   Poot, A A ^a,b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b AO FOUNDATION   (Switzerland)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Back pain; Biologically active agent; Cell and gene therapy; Delivery system; Intervertebral disc degeneration

Indexed keywords

GENE THERAPY; IMPLANTS (SURGICAL); TARGETED DRUG DELIVERY;

ACELLULAR TISSUES; ACTIVE AGENTS; BACK PAIN; CATABOLIC PROCESS; DELIVERY SYSTEMS; EXTRACELLULAR MATRIX PRODUCTION; INTER-VERTEBRAL DISC DEGENERATION; INTERVERTEBRAL DISCS;

CONTROLLED DRUG DELIVERY;

ADALIMUMAB; CLONIDINE; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; DICLOFENAC; EPIDERMAL GROWTH FACTOR; ETANERCEPT; GABAPENTIN; GROWTH FACTOR; IBUPROFEN; IMIPRAMINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KETOPROFEN; LIDOCAINE; METHYLPREDNISOLONE; MICROSPHERE; MORPHINE; OXYCODONE; PAROXETINE; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PREGABALIN; RETROVIRUS VECTOR; SMALL INTERFERING RNA; TOPIRAMATE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRIAMCINOLONE; UNINDEXED DRUG; BIOLOGICAL FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARTILAGE CELL; CELL THERAPY; CROSS LINKING; DISCOGENIC PAIN; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; GENE TARGETING; HUMAN; HYDROGEL; INTERVERTEBRAL DISK DEGENERATION; LOW BACK PAIN; MESENCHYMAL STEM CELL; NEUROPATHIC PAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; SUSTAINED DRUG RELEASE; TISSUE ENGINEERING; TISSUE SCAFFOLD; VIRAL GENE DELIVERY SYSTEM; GENE THERAPY; GENETICS; INTERVERTEBRAL DISC DEGENERATION; PROCEDURES;

BIOLOGICAL FACTORS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; INTERVERTEBRAL DISC DEGENERATION;

EID: 84929132507     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.024     Document Type: Review

References (246)

1. Andersson G.B.J. Epidemiological features of chronic low-back pain. Lancet 1999, 354:581-585.
2. Adams M.A., Roughley P.J. What is intervertebral disc degeneration, and what causes it?. Spine (Phila Pa 1976) 2006, 31:2151-2161.
3. Zhang Y.J., An H.S., Tannoury C., Thonar E.J.M.A., Freedman M.K., Anderson D.G. Biological treatment for degenerative disc disease. Am. J. Phys. Med. Rehabil. 2008, 87:694-702.
4. Andersson G.B. Epidemiologic aspects on low-back pain in industry. Spine (Phila Pa 1976) 1981, 6:53-60.
5. Borenstein D.G. Epidemiology, etiology, diagnostic evaluation, and treatment of low back pain. Curr. Opin. Rheumatol. 2001, 13:128-134.
6. Ala-Kokko L. Genetic risk factors for lumbar disc disease. Ann. Med. 2002, 34:42-47.
7. Matsui H., Kanamori M., Ishihara H., Yudoh K., Naruse Y., Tsuji H. Familial predisposition for lumbar degenerative disc disease - a case-control study. Spine (Phila Pa 1976) 1998, 23:1029-1034.
8. Urban J.P., Roberts S. Degeneration of the intervertebral disc. Arthritis Res. Ther. 2003, 5:120-130.
9. O'Halloran D.M., Pandit A.S. Tissue-engineering approach to regenerating the intervertebral disc. Tissue Eng. 2007, 13:1927-1954.
10. Mirza S.K., White A.A. Anatomy of intervertebral disc and pathophysiology of herniated disc disease. J. Clin. Laser Med. Surg. 1995, 13:131-142.
11. Setton L.A., Chen J. Cell mechanics and mechanobiology in the intervertebral disc. Spine (Phila Pa 1976) 2004, 29:2710-2723.
12. Whatley B.R., Wen X.J. Intervertebral disc (IVD): structure, degeneration, repair and regeneration. Mater Sci. Eng. C. Mater. Biol. Appl. 2012, 32:61-77.
13. Yang X.L., Li X.D. Nucleus pulposus tissue engineering: a brief review. Eur. Spine J. 2009, 18:1564-1572.
14. Guterl C.C., See E.Y., Blanquer S.B.G., Pandit A., Ferguson S.J., Benneker L.M., Grijpma D.W., Sakai D., Eglin D., Alini M., Iatridis J.C., Grad S. Challenges and strategies in the repair of ruptured annulus fibrosus. Eur. Cell. Mater. 2013, 25:1-21.
15. Antoniou J., Goudsouzian N.M., Heathfield T.F., Winterbottom N., Steffen T., Poole A.R., Aebi M., Alini M. The human lumbar endplate - evidence of changes in biosynthesis and denaturation of the extracellular matrix with growth, maturation, aging, and degeneration. Spine (Phila Pa 1976) 1996, 21:1153-1161.
16. Bibby S.R., Jones D.A., Lee R.B., Yu J., Urban J.P.G. The pathophysiology of the intervertebral disc. Joint Bone Spine 2001, 68:537-542.
17. Boubriak O.A., Watson N., Sivan S.S., Stubbens N., Urban J.P.G. Factors regulating viable cell density in the intervertebral disc: blood supply in relation to disc height. J. Anat. 2013, 222:341-348.
18. Urban J.P.G., Smith S., Fairbank J.C.T. Nutrition of the intervertebral disc. Spine (Phila Pa 1976) 2004, 29:2700-2709.
19. Lotz J.C., Kim A.J. Disc regeneration: why, when, and how. Neurosurg. Clin. N. Am. 2005, 16:657-663.
20. Bibby S.R.S., Urban J.P.G. Effect of nutrient deprivation on the viability of intervertebral disc cells. Eur. Spine J. 2004, 13:695-701.
21. Ratsep T., Minajeva A., Asser T. Relationship between neovascularization and degenerative changes in herniated lumbar intervertebral discs. Eur. Spine J. 2013, 22:2474-2480.
22. Freemont A.J., Peacock T.E., Goupille P., Hoyland J.A., OBrien J., Jayson M.I.V. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997, 350:178-181.
23. Frobin W., Brinckmann P., Kramer M., Hartwig E. Height of lumbar discs measured from radiographs compared with degeneration and height classified from MR images. Eur. Radiol. 2001, 11:263-269.
24. Urban J.P.G., Mcmullin J.F. Swelling pressure of the lumbar intervertebral disks - influence of age, spinal level, composition, and degeneration. Spine (Phila Pa 1976) 1988, 13:179-187.
25. Hutton W.C., Toribatake Y., Elmer W.A., Ganey T.M., Tomita K., Whitesides T.E. The effect of compressive force applied to the intervertebral disc in vivo. A study of proteoglycans and collagen. Spine (Phila Pa 1976) 1998, 23:2524-2537.
26. Iatridis J.C., Nicoll S.B., Michalek A.J., Walter B.A., Gupta M.S. Role of biomechanics in intervertebral disc degeneration and regenerative therapies: what needs repairing in the disc and what are promising biomaterials for its repair?. Spine J. 2013, 13:243-262.
27. Gruber H.E., Leslie K., Ingram J., Norton H.J., Hanley E.N. Cell-based tissue engineering for the intervertebral disc: in vitro studies of human disc cell gene expression and matrix production within selected cell carriers. Spine J. 2004, 4:44-55.
28. Roughley P.J. Biology of intervertebral disc aging and degeneration - involvement of the extracellular matrix. Spine (Phila Pa 1976) 2004, 29:2691-2699.
29. Kepler C.K., Ponnappan R.K., Tannoury C.A., Risbud M.V., Anderson D.G. The molecular basis of intervertebral disc degeneration. Spine J. 2013, 13:318-330.
30. Le Maitre C.L., Pockert A., Buttlet D.J., Freemont A.J., Hoyland J.A. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem. Soc. Trans. 2007, 35:652-655.
31. Roughley P.J., Melching L.I., Heathfield T.F., Pearce R.H., Mort J.S. The structure and degradation of aggrecan in human intervertebral disc. Eur. Spine J. 2006, 15:S326-S332.
32. Guiot B.H., Fessler R.G. Molecular biology of degenerative disc disease. Neurosurgery 2000, 47:1034-1040.
33. Antoniou J., Steffen T., Nelson F., Winterbottom N., Hollander A.P., Poole R.A., Aebi M., Alini M. The human lumbar intervertebral disc - evidence for changes in the biosynthesis and denaturation of the extracellular matrix with growth, maturation, ageing, and degeneration. J. Clin. Invest. 1996, 98:996-1003.
34. Risbud M.V., Shapiro I.M. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat. Rev. Rheumatol. 2014, 10:44-56.
35. Le Maitre C.L., Hoyland J.A., Freemont A.J. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1 beta and TNF alpha expression profile. Arthritis Res. Ther. 2007, 9:R77.
36. Hoyland J.A., Le Maitre C., Freemont A.J. Investigation of the role of IL-1 and TNF in matrix degradation in the intervertebral disc. Rheumatology 2008, 47:809-814.
37. Kang J.D., StefanovicRacic M., McIntyre L.A., Georgescu H.I., Evans C.H. Toward a biochemical understanding of human intervertebral disc degeneration and herniation - contributions of nitric oxide, interleukins, prostaglandin E-2, and matrix metalloproteinases. Spine (Phila Pa 1976) 1997, 22:1065-1073.
38. Roberts S., Caterson B., Menage J., Evans E.H., Jaffray D.C., Eisenstein S.M. Matrix metalloproteinases and aggrecanase - their role in disorders of the human intervertebral disc. Spine (Phila Pa 1976) 2000, 25:3005-3013.
39. Le Maitre C.L., Freemont A.J., Hoyland J.A. Human disc degeneration is associated with increased MMP 7 expression. Biotech. Histochem. 2006, 81:125-131.
40. Ariga K., Yonenobu K., Nakase T., Kaneko M., Okuda S., Uchiyama Y., Yoshikawa H. Localization of cathepsins D, K, and L in degenerated human intervertebral discs. Spine (Phila Pa 1976) 2001, 26:2666-2672.
41. Goupille P., Jayson M.I.V., Valat J.P., Freemont A.J. Matrix metalloproteinases: the clue to intervertebral disc degeneration?. Spine (Phila Pa 1976) 1998, 23:1612-1626.
42. Horner H.A., Urban J.P.G. 2001 Volvo Award winner in basic science studies: effect of nutrient supply on the viability of cells from the nucleus pulposus of the intervertebral disc. Spine (Phila Pa 1976) 2001, 26:2543-2549.
43. Ohshima H., Urban J.P. The effect of lactate and pH on proteoglycan and protein synthesis rates in the intervertebral disc. Spine (Phila Pa 1976) 1992, 17:1079-1082.
44. de Castro I., dos Santos D.P., Christoph D.H., Landeiro J.A. The history of spinal surgery for disc disease - an illustrated timeline. Arq. Neuropsiquiatr. 2005, 63:701-706.
45. Bao Q.B., McCullen G.M., Higham P.A., Dumbleton J.H., Yuan H.A. The artificial disc: theory, design and materials. Biomaterials 1996, 17:1157-1167.
46. Buttner-Janz K., Hahn S., Schikora K., Link H.D. Basic principles of successful implantation of the SB Charite model LINK intervertebral disk endoprosthesis. Orthopade 2002, 31:441-453.
47. Ahlgren B.D., Lui W., Herkowitz H.N., Panjabi M.M., Guiboux J.P. Effect of annular repair on the healing strength of the intervertebral disc: a sheep model. Spine (Phila Pa 1976) 2000, 25:2165-2170.
48. Denoziere G., Ku D.N. Biomechanical comparison between fusion of two vertebrae and implantation of an artificial intervertebral disc. J. Biomech. 2006, 39:766-775.
49. Disch A.C., Schmoelz W., Matziolis G., Schneider S.V., Knop C., Putzier M. Higher risk of adjacent segment degeneration after floating fusions: long-term outcome after low lumbar spine fusions. J. Spinal Disord. Tech. 2008, 21:79-85.
50. Lee S.H., Shin H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv. Rev. 2007, 59:339-359.
51. Sittinger M., Hutmacher D.W., Risbud M.V. Current strategies for cell delivery in cartilage and bone regeneration. Curr. Opin. Biotechnol. 2004, 15:411-418.
52. Low S.A., Kopecek J. Targeting polymer therapeutics to bone. Adv. Drug Deliv. Rev. 2012, 64:1189-1204.
53. Vo T.N., Kasper F.K., Mikos A.G. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv. Drug Deliv. Rev. 2012, 64:1292-1309.
54. Schnitzer T.J., Ferraro A., Hunsche E., Kong S.X. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J. Pain Symptom Manage. 2004, 28:72-95.
55. Airaksinen O., Brox J.I., Cedraschi C., Hildebrandt J., Klaber-Moffett J., Kovacs F., Mannion A.F., Reis S., Staal J.B., Ursin H., Zanoli G., C.B.W.G.G.Ch Chapter 4 - European guidelines for the management of chronic nonspecific low back pain. Eur. Spine J. 2006, 15:S192-S300.
56. Chou R., Huffman L.H. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann. Intern. Med. 2007, 147:505-514.
57. Rho M.E., Tang C.T. The efficacy of lumbar epidural steroid injections: transforaminal, interlaminar, and caudal approaches. Phys. Med. Rehabil. Clin. N. Am. 2011, 22:139-148.
58. Wilkinson I., Cohen S.P. Epidural steroids for spinal pain and radiculopathy: a narrative, evidence-based review. Curr. Opin. Anesthesiol. 2013, 26:562-572.
59. Chung J.W., Zeng Y., Wong T.K. Drug therapy for the treatment of chronic nonspecific low back pain: systematic review and meta-analysis. Pain Physician 2013, 16:E685-E704.
60. McLain R.F., Kapural L., Mekhail N.A. Epidural steroid therapy for back and leg pain: mechanisms of action and efficacy. Spine J. 2005, 5:191-201.
61. Stafford M.A., Peng P., Hill D.A. Sciatica: a review of history, epidemiology, pathogenesis, and the role of epidural steroid injection in management. Br. J. Anaesth. 2007, 99:461-473.
62. Cervera-Irimia J., Tome-Bermejo F. Caudal epidural steroid injection in the treatment of chronic discogenic low back pain. Comparative, prospective and randomized study. Rev. Esp. Cir. Ortop. Traumatol. 2013, 57:324-332.
63. Lee J.H., Moon J., Lee S.H. Comparison of effectiveness according to different approaches of epidural steroid injection in lumbosacral herniated disk and spinal stenosis. J. Back Musculoskelet. Rehabil. 2009, 22:83-89.
64. Manchikanti L., Singh V., Falco F.J., Cash K.A., Pampati V. Evaluation of the effectiveness of lumbar interlaminar epidural injections in managing chronic pain of lumbar disc herniation or radiculitis: a randomized, double-blind, controlled trial. Pain Physician 2010, 13:343-355.
65. Roberts S.T., Willick S.E., Rho M.E., Rittenberg J.D. Efficacy of lumbosacral transforaminal epidural steroid injections: a systematic review. PM R 2009, 1:657-668.
66. Kuritzky L., Samraj G.P. Nonsteroidal anti-inflammatory drugs in the treatment of low back pain. J. Pain Res. 2012, 5:579-590.
67. Yoshida T., Park J.S., Yokosuka K., Jimbo K., Yamada K., Sato K., Nagata K. Effect of a nonprotein bioactive agent on the reduction of cyclooxygenase-2 and tumor necrosis factor-alpha in human intervertebral disc cells in vitro. J. Neurosurg. Spine 2008, 9:411-418.
68. Cornefjord M., Olmarker K., Otani K., Rydevik B. Nucleus pulposus-induced nerve root injury: effects of diclofenac and ketoprofen. Eur. Spine J. 2002, 11:57-61.
69. Veenema K.R., Leahey N., Schneider S. Ketorolac versus meperidine: ED treatment of severe musculoskeletal low back pain. Am. J. Emerg. Med. 2000, 18:404-407.
70. Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide - results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila Pa 1976) 2000, 25:1579-1585.
71. Almaawi A., Wang H.T., Ciobanu O., Rowas S.A., Rampersad S., Antoniou J., Mwale F. Effect of acetaminophen and nonsteroidal anti-inflammatory drugs on gene expression of mesenchymal stem cells. Tissue Eng. Part A 2013, 19:1039-1046.
72. Coats T.L., Borenstein D.G., Nangia N.K., Brown M.T. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clin. Ther. 2004, 26:1249-1260.
73. Birbara C.A., Puopolo A.D., Munoz D.R., Sheldon E.A., Mangione A., Bohidar N.R., Geba G.P., Grp E.P.S. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability - a randomized, placebo-controlled, 3-month trial. J. Pain 2003, 4:307-315.
74. van Tulder M.W., Scholten R.J., Koes B.W., Deyo R.A. Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group. Spine (Phila Pa 1976) 2000, 25:2501-2513.
75. Koes B.W., Scholten R.J.P.M., Mens J.M.A., Bouter L.M. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann. Rheum. Dis. 1997, 56:214-223.
76. Schnitzer T.J., Gray W.L., Paster R.Z., Kamin M. Efficacy of tramadol in treatment of chronic low back pain. J. Rheumatol. 2000, 27:772-778.
77. Gordon A., Rashiq S., Moulin D.E., Clark A.J., Beaulieu A.D., Eisenhoffer J., Piraino P.S., Quigley P., Harsanyi Z., Darke A.C. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res. Manag. 2010, 15:169-178.
78. Khoromi S., Cui L., Nackers L., Max M.B. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007, 130:66-75.
79. van Tulder M.W., Touray T., Furlan A.D., Solway S., Bouter L.M. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane Collaboration. Spine (Phila Pa 1976) 2003, 28:1978-1992.
80. Cherkin D.C., Wheeler K.J., Barlow W., Deyo R.A. Medication use for low back pain in primary care. Spine (Phila Pa 1976) 1998, 23:607-614.
81. Arbus L., Fajadet B., Aubert D., Morre M., Goldberger E. Activity of tetrazepam (myolastan) in low-back-pain - a double-blind trial V placebo. Clin. Trials J. 1990, 27:258-267.
82. Staiger T.O., Gaster B., Sullivan M.D., Deyo R.A. Systematic review of antidepressants in the treatment of chronic low back pain. Spine (Phila Pa 1976) 2003, 28:2540-2545.
83. Salerno S.M., Browning R., Jackson J.L. The effect of antidepressant treatment on chronic back pain: a meta-analysis. Arch. Intern. Med. 2002, 162:19-24.
84. Grice G.R., Mertens M.K. Gabapentin as a potential option for treatment of sciatica. Pharmacotherapy 2008, 28:397-402.
85. Muehlbacher M., Nickel M.K., Kettler C., Tritt K., Lahmann C., Leiberich P.K., Nickel C., Krawczyk J., Mitterlehner F.O., Rother W.K., Loew T.H., Kaplan P. Topiramate in treatment of patients with chronic low back pain: a randomized, double-blind, placebo-controlled study. Clin. J. Pain 2006, 22:526-531.
86. Saldana M.T., Navarro A., Perez C., Masramon X., Rejas J. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol. Int. 2010, 30:1005-1015.
87. Karppinen J., Korhonen T., Malmivaara A., Paimela L., Kyllonen E., Lindgren K.A., Rantanen P., Tervonen O., Niinimaki J., Seitsalo S., Hurri H. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine (Phila Pa 1976) 2003, 28:750-753.
88. Genevay S., Stingelin S., Gabay C. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. Ann. Rheum. Dis. 2004, 63:1120-1123.
89. Pimentel D.C., El Abd O., Benyamin R.M., Buehler A.M., Leite V.F., Mazloomdoost D., Chen J., Hsing W.T., Amadera J.E.D. Anti-tumor necrosis factor antagonists in the treatment of low back pain and radiculopathy: a systematic review and meta-analysis. Pain Physician 2014, 17:E27-E44.
90. Ersayli D.T., Gurbet A., Bekar A., Uckunkaya N., Bilgin H. Effects of perioperatively administered bupivacaine and bupivacaine-methylprednisolone on pain after lumbar discectomy. Spine (Phila Pa 1976) 2006, 31:2221-2226.
91. Glynn C., O'Sullivan K. A double-blind randomised comparison of the effects of epidural clonidine, lignocaine and the combination of clonidine and lignocaine in patients with chronic pain. Pain 1996, 64:337-343.
92. Burgher A.H., Hoelzer B.C., Schroeder D.R., Wilson G.A., Huntoon M.A. Transforaminal epidural clonidine versus corticosteroid for acute lumbosacral radiculopathy due to intervertebral disc herniation. Spine (Phila Pa 1976) 2011, 36:E293-E300.
93. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain - a randomized, double-blind study. Neurology 2001, 56:1290-1293.
94. Wei M., Mo S.L., Nabar N.R., Chen Y.L., Zhang J.J., He Q.L., Zou X.N., Liu X.G., Sun L.B., Zhou S.F. Modification of rat model of sciatica induced by lumber disc herniation and the anti-inflammatory effect of osthole given by epidural catheterization. Pharmacology 2012, 90:251-263.
95. Sinclair S.M., Bhattacharyya J., McDaniel J.R., Gooden D.M., Gopalaswamy R., Chilkoti A., Setton L.A. A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation. J. Control. Release 2013, 171:38-47.
96. Klawitter M., Quero L., Klasen J., Gloess A.N., Klopprogge B., Hausmann O., Boos N., Wuertz K. Curcuma DMSO extracts and curcumin exhibit an anti-inflammatory and anti-catabolic effect on human intervertebral disc cells, possibly by influencing TLR2 expression and JNK activity. J. Inflamm. (Lond) 2012, 9:29.
97. Wuertz K., Quero L., Sekiguchi M., Klawitter M., Nerlich A., Konno S.I., Kikuchi S.I., Boos N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976) 2011, 36:E1373-E1384.
98. Orita S., Miyagi M., Kobori S., Gemba T., Ishikawa T., Inoue G., Toyone T., Aoki Y., Eguchi Y., Takahashi K., Ohtori S. I kappa B kinase beta inhibitor downregulates pain-related neuropeptide production in the sensory neurons innervating injured lumbar intervertebral discs in the dorsal root ganglia of rats. Spine J. 2013, 13:284-288.
99. Nasto L.A., Seo H.Y., Robinson A.R., Tilstra J.S., Clauson C.L., Sowa G.A., Ngo K., Dong Q., Pola E., Lee J.Y., Niedernhofer L.J., Kang J.D., Robbins P.D., Vo N.V. ISSLS prize winner: inhibition of NF-kappa B activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging. Spine (Phila Pa 1976) 2012, 37:1819-1825.
100. Suzuki M., Inoue G., Gemba T., Watanabe T., Ito T., Koshi T., Yamauchi K., Yamashita M., Orita S., Eguchi Y., Ochiai N., Kishida S., Takaso M., Aoki Y., Takahashi K., Ohtori S. Nuclear factor-kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model. Eur. Spine J. 2009, 18:1001-1007.
101. Wuertz K., Vo N., Kletsas D., Boos N. Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-kappaB and MAP kinases. Eur. Cell. Mater. 2012, 23:103-119. (discussion 119-120).
102. Yoon S.T., Patel N.M. Molecular therapy of the intervertebral disc. Eur. Spine J. 2006, 15:S379-S388.
103. Masuda K., An H.S. Growth factors and the intervertebral disc. Spine J. 2004, 4:330S-340S.
104. Ireland D. Molecular mechanisms involved in intervertebral disc degeneration and potential new treatment strategies. Biosci. Horiz. 2009, 2:83-89.
105. Masuda K. Biological repair of the degenerated intervertebral disc by the injection of growth factors. Eur. Spine J. 2008, 17:S441-S451.
106. Masuda K., Oegema T.R., An H.S. Growth factors and treatment of intervertebral disc degeneration. Spine (Phila Pa 1976) 2004, 29:2757-2769.
107. Walsh A.J.L., Bradford D.S., Lotz J.C. In vivo growth factor treatment of degenerated intervertebral discs. Spine (Phila Pa 1976) 2004, 29:156-163.
108. Reddi A.H. Morphogenetic messages are in the extracellular matrix: biotechnology from bench to bedside. Biochem. Soc. Trans. 2000, 28:345-349.
109. Michalek A.J., Buckley M.R., Bonassar L.J., Cohen I., Iatridis J.C. The effects of needle puncture injury on microscale shear strain in the intervertebral disc annulus fibrosus. Spine J. 2010, 10:1098-1105.
110. Kang J.D. Does a needle puncture into the annulus fibrosus cause disc degeneration?. Spine J. 2010, 10:1106-1107.
111. Poynton A.R., Lane J.M. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976) 2002, 27:S40-S48.
112. Ganey T.M., Meisel H.J. A potential role for cell-based therapeutics in the treatment of intervertebral disc herniation. Eur. Spine J. 2002, 11(Suppl. 2):S206-S214.
113. Orozco L., Soler R., Morera C., Alberca M., Sanchez A., Garcia-Sancho J. Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation 2011, 92:822-828.
114. Grad S., Alini M., Eglin D., Sakai D., Nochida J., Nahor S., Collin E., Dash B., Pandit A. Cells and Biomaterials for Intervertebral Disc Regeneration 2010, Morgan & Claypool, San Rafael.
115. Vert M. Polymeric biomaterials: strategies of the past vs. strategies of the future. Prog. Polym. Sci. 2007, 32:755-761.
116. Nair L.S., Laurencin C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci. 2007, 32:762-798.
117. Griffith L.G. Polymeric biomaterials. Acta Mater. 2000, 48:263-277.
118. Friess W. Collagen - biomaterial for drug delivery. Eur. J. Pharm. Biopharm. 1998, 45:113-136.
119. Meyers M.A., Chen P.Y., Lin A.Y.M., Seki Y. Biological materials: structure and mechanical properties. Prog. Mater. Sci. 2008, 53:1-206.
120. Vert M., Li S.M., Spenlehauer G., Guerin P. Bioresorbability and biocompatibility of aliphatic polyesters. J. Mater. Sci. Mater. Med. 1992, 3:432-446.
121. Beall D.P., Deer T.R., Wilsey J.T., Walsh A.J.L., Block J.H., McKay W.F., Zanella J.M. Tissue distribution of clonidine following intraforaminal implantation of biodegradable pellets: potential alternative to epidural steroid for radiculopathy. Pain Physician 2012, 15:E701-E710.
122. Zanella J.M., Burright E.N., Hildebrand K., Hobot C., Cox M., Christoferson L., McKay W.F. Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine (Phila Pa 1976) 2008, 33:227-234.
123. Nerurkar N.L., Baker B.M., Sen S., Wible E.E., Elliott D.M., Mauck R.L. Nanofibrous biologic laminates replicate the form and function of the annulus fibrosus. Nat. Mater. 2009, 8:986-992.
124. Koepsell L., Zhang L.F., Neufeld D., Fong H., Deng Y. Electrospun nanofibrous polycaprolactone scaffolds for tissue engineering of annulus fibrosus. Macromol. Biosci. 2011, 11:391-399.
125. Vadala G., Mozetic P., Rainer A., Centola M., Loppini M., Trombetta M., Denaro V. Bioactive electrospun scaffold for annulus fibrosus repair and regeneration. Eur. Spine J. 2012, 21:S20-S26.
126. Pham Q.P., Sharma U., Mikos A.G. Electrospinning of polymeric nanofibers for tissue engineering applications: a review. Tissue Eng. 2006, 12:1197-1211.
127. Sharma S.K., Jones J.O., Zeballos P.P., Irwin S.A., Martin T.W. The prevention of discitis during discography. Spine J. 2009, 9:936-943.
128. Bao J., Lv W., Sun Y.Y., Deng Y. Electrospun antimicrobial microfibrous scaffold for annulus fibrosus tissue engineering. J. Mater. Sci. 2013, 48:4223-4232.
129. Tegos G., Stermitz F.R., Lomovskaya O., Lewis K. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob. Agents Chemother. 2002, 46:3133-3141.
130. Blanquer S.B.G., Sharifi S., Grijpma D.W. Development of poly(trimethylene carbonate) network implants for annulus fibrosus tissue engineering. J. Appl. Biomater. Funct. Mater. 2012, 10:177-184.
131. Blanquer S.B.G., Haimi S.P., Poot A.A., Grijpma D.W. Effect of pore characteristics on mechanical properties and annulus fibrosus cell seeding and proliferation in designed PTMC tissue engineering scaffolds. Macromol. Symp. 2013, 334:75-81.
132. Hegewald A.A., Zouhair S., Endres M., Cabraja M., Woiciechowsky C., Thome C., Kaps C. Towards biological annulus repair: TGF-beta 3, FGF-2 and human serum support matrix formation by human annulus fibrosus cells. Tissue Cell 2013, 45:68-76.
133. Guillaume O., Daly A., Lennon K., Gansau J., Buckley S.F., Buckley C.T. Shape-memory porous alginate scaffolds for regeneration of the annulus fibrosus: effect of TGF-beta 3 supplementation and oxygen culture conditions. Acta Biomater. 2014, 10:1985-1995.
134. Gorth D.J., Mauck R.L., Chiaro J.A., Mohanraj B., Hebela N.M., Dodge G.R., Elliott D.M., Smith L.J. IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1 beta-mediated degradation of nucleus pulposus in vitro. Arthritis Res. Ther. 2012, 14:R179.
135. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., Morrell C. Biologically erodable microsphere as potential oral drug delivery system. Nature 1997, 386:410-414.
136. Freiberg S., Zhu X. Polymer microspheres for controlled drug release. Int. J. Pharm. 2004, 282:1-18.
137. Ragab A.A., Woodall J.W., Tucci M.A., Wingerter S.A., Fosnaugh A.W., Franklin L.N., Benghuzzi H.A. A preliminary report on the effects of sustained administration of corticosteroid on traumatized disc using the adult male rat model. J. Spinal Disord. Tech. 2009, 22:473-478.
138. Le Maitre C.L., Freemont A.J., Hoyland J.A. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res. Ther. 2005, 7:R732-R745.
139. Liang C.Z., Li H., Tao Y.Q., Peng L.H., Gao J.Q., Wu J.J., Li F.C., Hua J.M., Chen Q.X. Dual release of dexamethasone and TGF-beta 3 from polymeric microspheres for stem cell matrix accumulation in a rat disc degeneration model. Acta Biomater. 2013, 9:9423-9433.
140. Liang C.Z., Li H., Tao Y.Q., Zhou X.P., Yang Z.R., Xiao Y.X., Li F.C., Han B., Chen Q.X. Dual delivery for stem cell differentiation using dexamethasone and bFGF in/on polymeric microspheres as a cell carrier for nucleus pulposus regeneration. J Mater Sci-Mater M 2012, 23:1097-1107.
141. Kim S., Kim J.C., Sul D., Hwang S.W., Lee S.H., Kim Y.H., Tae G. Nanoparticle formulation for controlled release of capsaicin. J. Nanosci. Nanotechnol. 2011, 11:4586-4591.
142. Winter J., Bevan S., Campbell E.A. Capsaicin and pain mechanisms. Br. J. Anaesth. 1995, 75:157-168.
143. Van Vlierberghe S., Dubruel P., Schacht E. Biopolymer-based hydrogels as scaffolds for tissue engineering applications: a review. Biomacromolecules 2011, 12:1387-1408.
144. Lee K.Y., Mooney D.J. Hydrogels for tissue engineering. Chem. Rev. 2001, 101:1869-1879.
145. Hoare T.R., Kohane D.S. Hydrogels in drug delivery: progress and challenges. Polymer 2008, 49:1993-2007.
146. Hennink W.E., van Nostrum C.F. Novel crosslinking methods to design hydrogels. Adv. Drug Deliv. Rev. 2012, 64:223-236.
147. Van Tomme S.R., Storm G., Hennink W.E. In situ gelling hydrogels for pharmaceutical and biomedical applications. Int. J. Pharm. 2008, 355:1-18.
148. Kretlow J.D., Klouda L., Mikos A.G. Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 2007, 59:263-273.
149. Alini M., Li W., Markovic P., Aebi M., Spiro R.C., Roughley P.J. The potential and limitations of a cell-seeded collagen/hyaluronan scaffold to engineer an intervertebral disc-like matrix. Spine (Phila Pa 1976) 2003, 28:446-453.
150. Gombotz W.R., Wee S.F. Protein release from alginate matrices. Adv. Drug Deliv. Rev. 2012, 64:194-205.
151. Demol J., Lambrechts D., Geris L., Schrooten J., Van Oosterwyck H. Towards a quantitative understanding of oxygen tension and cell density evolution in fibrin hydrogels. Biomaterials 2011, 32:107-118.
152. Mwale F., Ciobanu I., Giannitsios D., Roughley P., Steffen T., Antoniou J. Effect of oxygen levels on proteoglycan synthesis by intervertebral disc cells. Spine (Phila Pa 1976) 2011, 36:E131-E138.
153. Imai Y., Miyamoto K., An H.S., Thonar E.J., Andersson G.B., Masuda K. Recombinant human osteogenic protein-1 upregulates proteoglycan metabolism of human annulus fibrosus and nucleus pulposus cells. Spine (Phila Pa 1976) 2007, 32:1303-1309. (discussion 1310).
154. Gruber H.E., Fisher E.C., Desai B., Stasky A.A., Hoelscher G., Hanley E.N. Human intervertebral disc cells from the annulus: three-dimensional culture in agarose or alginate and responsiveness to TGF-beta 1. Exp. Cell Res. 1997, 235:13-21.
155. Akeda K., An H.S., Pichika R., Attawia M., Thonar E.J.M.A., Lenz M.E., Uchida A., Masuda K. Platelet-rich plasma (PRP) stimulates the extracellular matrix metabolism of porcine nucleus pulposus and annulus fibrosus cells cultured in alginate beads. Spine (Phila Pa 1976) 2006, 31:959-966.
156. Shen B.J., Wei A.Q., Tao H.L., Diwan A.D., Ma D.D.F. BMP-2 enhances TGF-beta 3-mediated chondrogenic differentiation of human bone marrow multipotent mesenchymal stromal cells in alginate bead culture. Tissue Eng. Part A 2009, 15:1311-1320.
157. Sawamura K., Ikeda T., Nagae M., Okamoto S., Mikami Y., Hase H., Ikoma K., Yamada T., Sakamoto H., Matsuda K., Tabata Y., Kawata M., Kubo T. Characterization of in vivo effects of platelet-rich plasma and biodegradable gelatin hydrogel microspheres on degenerated intervertebral discs. Tissue Eng. Part A 2009, 15:3719-3727.
158. Nagae M., Ikeda T., Mikami Y., Hase H., Ozawa H., Matsuda K.I., Sakamot H., Tabata Y., Kawata M., Kubo T. Intervertebral disc regeneration using platelet-rich plasma and biodegradable gelatin hydrogel microspheres. Tissue Eng. 2007, 13:147-158.
159. Nguyen K.T., West J.L. Photopolymerizable hydrogels for tissue engineering applications. Biomaterials 2002, 23:4307-4314.
160. Elisseeff J., Anseth K., Sims D., McIntosh W., Randolph M., Langer R. Transdermal photopolymerization for minimally invasive implantation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3104-3107.
161. Chou A.I., Nicoll S.B. Characterization of photocrosslinked alginate hydrogels for nucleus pulposus cell encapsulation. J. Biomed. Mater. Res. A 2009, 91A:187-194.
162. Chou A.I., Akintoye S.O., Nicoll S.B. Photo-crosslinked alginate hydrogels support enhanced matrix accumulation by nucleus pulposus cells in vivo. Osteoarthritis Cartilage 2009, 17:1377-1384.
163. Bouhadir K.H., Lee K.Y., Alsberg E., Damm K.L., Anderson K.W., Mooney D.J. Degradation of partially oxidized alginate and its potential application for tissue engineering. Biotechnol. Prog. 2001, 17:945-950.
164. Reza A.T., Nicoll S.B. Characterization of novel photocrosslinked carboxymethylcellulose hydrogels for encapsulation of nucleus pulposus cells. Acta Biomater. 2010, 6:179-186.
165. Gupta M.S., Cooper E.S., Nicoll S.B. Transforming growth factor-beta 3 stimulates cartilage matrix elaboration by human marrow-derived stromal cells encapsulated in photocrosslinked carboxymethylcellulose hydrogels: potential for nucleus pulposus replacement. Tissue Eng. Part A 2011, 17:2903-2910.
166. Frith J.E., Cameron A.R., Menzies D.J., Ghosh P., Whitehead D.L., Gronthos S., Zannettino A.C.W., Cooper-White J.J. An injectable hydrogel incorporating mesenchymal precursor cells and pentosan polysulphate for intervertebral disc regeneration. Biomaterials 2013, 34:9430-9440.
167. Frith J.E., Menzies D.J., Cameron A.R., Ghosh P., Whitehead D.L., Gronthos S., Zannettino A.C.W., Cooper-White J.J. Effects of bound versus soluble pentosan polysulphate in PEG/HA-based hydrogels tailored for intervertebral disc regeneration. Biomaterials 2014, 35:1150-1162.
168. Halloran D.O., Grad S., Stoddart M., Dockery P., Alini M., Pandit A.S. An injectable cross-linked scaffold for nucleus pulposus regeneration. Biomaterials 2008, 29:438-447.
169. Collin E.C., Grad S., Zeugolis D.I., Vinatier C.S., Clouet J.R., Guicheux J.J., Weiss P., Alini M., Pandit A.S. An injectable vehicle for nucleus pulposus cell-based therapy. Biomaterials 2011, 32:2862-2870.
170. Chen Y.C., Su W.Y., Yang S.H., Gefen A., Lin F.H. In situ forming hydrogels composed of oxidized high molecular weight hyaluronic acid and gelatin for nucleus pulposus regeneration. Acta Biomater. 2013, 9:5181-5193.
171. Su W.Y., Chen Y.C., Lin F.H. Injectable oxidized hyaluronic acid/adipic acid dihydrazide hydrogel for nucleus pulposus regeneration. Acta Biomater. 2010, 6:3044-3055.
172. Francisco A.T., Mancino R.J., Bowles R.D., Brunger J.M., Tainter D.M., Chen Y.T., Richardson W.J., Guilak F., Setton L.A. Injectable laminin-functionalized hydrogel for nucleus pulposus regeneration. Biomaterials 2013, 34:7381-7388.
173. Moss I.L., Gordon L., Woodhouse K.A., Whyne C.M., Yee A.J.M. A novel thiol-modified hyaluronan and elastin-like polypeptide composite material for tissue engineering of the nucleus pulposus of the intervertebral disc. Spine (Phila Pa 1976) 2011, 36:1022-1029.
174. Mwale F., Iordanova M., Demers C.N., Steffen T., Roughley P., Antoniou J. Biological evaluation of chitosan salts cross-linked to genipin as a cell scaffold for disk tissue engineering. Tissue Eng. 2005, 11:130-140.
175. Schek R.M., Michalek A.J., Iatridis J.C. Genipin-crosslinked fibrin hydrogels as a potential adhesive to augment intervertebral disc annulus repair. Eur. Cell. Mater. 2011, 21:373-383.
176. Day A.J., de la Motte C.A. Hyaluronan cross-linking: a protective mechanism in inflammation?. Trends Immunol. 2005, 26:637-643.
177. Shah M.A., Ebert A.M., Sanders W.E. Fibrin glue fixation of a digital osteochondral fracture: case report and review of the literature. J. Hand Surg. Am. Vol. 2002, 27A:464-469.
178. Iatridis J.C., Setton L.A., Weidenbaum M., Mow V.C. The viscoelastic behavior of the non-degenerate human lumbar nucleus pulposus in shear. J. Biomech. 1997, 30:1005-1013.
179. Iatridis J.C., Weidenbaum M., Setton L.A., Mow V.C. Is the nucleus pulposus a solid or a fluid? Mechanical behaviors of the nucleus pulposus of the human intervertebral disc. Spine (Phila Pa 1976) 1996, 21:1174-1184.
180. Cloyd J.M., Malhotra N.R., Weng L., Chen W., Mauck R.L., Elliott D.M. Material properties in unconfined compression of human nucleus pulposus, injectable hyaluronic acid-based hydrogels and tissue engineering scaffolds. Eur. Spine J. 2007, 16:1892-1898.
181. Recuerda M., Cote S.P., Villemure I., Perie D. Influence of experimental protocols on the mechanical properties of the intervertebral disc in unconfined compression. J. Biomech. Eng. 2011, 133:071006.
182. Sharifi S., Bulstra S.K., Grijpma D.W., Kuijer R. Treatment of the degenerated intervertebral disc; closure, repair and regeneration of the annulus fibrosus. J. Tissue Eng. Regen. Med. 2014, 10.1002/term.1866.
183. Bron J.L., Helder M.N., Meisel H.J., Van Royen B.J., Smit T.H. Repair, regenerative and supportive therapies of the annulus fibrosus: achievements and challenges. Eur. Spine J. 2009, 18:301-313.
184. Qiu Y., Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev. 2012, 64:49-60.
185. Ruel-Gariepy E., Leroux J.C. In situ-forming hydrogels - review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 2004, 58:409-426.
186. Klouda L., Mikos A.G. Thermoresponsive hydrogels in biomedical applications. Eur. J. Pharm. Biopharm. 2008, 68:34-45.
187. Chilkoti A., Dreher M.R., Meyer D.E., Raucher D. Targeted drug delivery by thermally responsive polymers. Adv. Drug Deliv. Rev. 2002, 54:613-630.
188. Nettles D.L., Chilkoti A., Setton L.A. Applications of elastin-like polypeptides in tissue engineering. Adv. Drug Deliv. Rev. 2010, 62:1479-1485.
189. MacEwan S.R., Chilkoti A. Elastin-like polypeptides: biomedical applications of tunable biopolymers. Biopolymers 2010, 94:60-77.
190. Christensen T., Hassouneh W., Trabbic-Carlson K., Chilkoti A. Predicting transition temperatures of elastin-like polypeptide fusion proteins. Biomacromolecules 2013, 14:1514-1519.
191. Shamji M.F., Betre H., Kraus V.B., Chen J., Chilkoti A., Pichika R., Masuda K., Setton L.A. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist - sustained release of a local antiinflammatory therapeutic. Arthritis Rheum. US 2007, 56:3650-3661.
192. Shamji M.F., Jing L.F., Chen J., Hwang P., Ghodsizadeh O., Friedman A.H., Richardson W.J., Setton L.A. Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier. J. Neurosurg. Spine 2008, 9:221-228.
193. Shamji M.F., Whitlatch L., Friedman A.H., Richardson W.J., Chilkoti A., Setton L.A. An injectable and in situ-gelling biopolymer for sustained drug release following perineural administration. Spine (Phila Pa 1976) 2008, 33:748-754.
194. Chenite A., Chaput C., Wang D., Combes C., Buschmann M.D., Hoemann C.D., Leroux J.C., Atkinson B.L., Binette F., Selmani A. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000, 21:2155-2161.
195. He P., Davis S.S., Illum L. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. 1998, 166:75-88.
196. Berger J., Reist M., Mayer J.M., Felt O., Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur. J. Pharm. Biopharm. 2004, 57:35-52.
197. Cho J.Y., Heuzey M.C., Begin A., Carreau P.J. Physical gelation of chitosan in the presence of beta-glycerophosphate: the effect of temperature. Biomacromolecules 2005, 6:3267-3275.
198. Roughley P., Hoemann C., DesRosiers E., Mwale F., Antoniou J., Alini M. The potential of chitosan-based gels containing intervertebral disc cells for nucleus pulposus supplementation. Biomaterials 2006, 27:388-396.
199. Richardson S.M., Hughes N., Hunt J.A., Freemont A.J., Hoyland J.A. Human mesenchymal stem cell differentiation to NP-like cells in chitosan-glycerophosphate hydrogels. Biomaterials 2008, 29:85-93.
200. Cheng Y.H., Yang S.H., Su W.Y., Chen Y.C., Yang K.C., Cheng W.T.K., Wu S.C., Lin F.H. Thermosensitive chitosan-gelatin-glycerol phosphate hydrogels as a cell carrier for nucleus pulposus regeneration: an in vitro study. Tissue Eng. Part A 2010, 16:695-703.
201. Cheng Y.H., Yang S.H., Lin F.H. Thermosensitive chitosan-gelatin-glycerol phosphate hydrogel as a controlled release system of ferulic acid for nucleus pulposus regeneration. Biomaterials 2011, 32:6953-6961.
202. Cheng Y.H., Yang S.H., Liu C.C., Gefen A., Lin F.H. Thermosensitive hydrogel made of ferulic acid-gelatin and chitosan glycerophosphate. Carbohydr. Polym. 2013, 92:1512-1519.
203. Yu L., Ding J.D. Injectable hydrogels as unique biomedical materials. Chem. Soc. Rev. 2008, 37:1473-1481.
204. Zhang H.N., Wang L., Park J.B., Park P., Yang V.C., Hollister S.J., La Marca F., Lin C.Y. Intradiscal injection of simvastatin retards progression of intervertebral disc degeneration induced by stab injury. Arthritis Res. Ther. 2009, 11:R172.
205. Jeong B., Kim S.W., Bae Y.H. Thermosensitive sol-gel reversible hydrogels. Adv. Drug Deliv. Rev. 2012, 64:154-162.
206. Peroglio M., Eglin D., Benneker L.M., Alini M., Grad S. Thermoreversible hyaluronan-based hydrogel supports in vitro and ex vivo disc-like differentiation of human mesenchymal stem cells. Spine J. 2013, 13:1627-1639.
207. Fraylich M.R., Liu R.X., Richardson S.M., Baird P., Hoyland J., Freemont A.J., Alexander C., Shakesheff K., Cellesi F., Saunders B.R. Thermally-triggered gelation of PLGA dispersions: towards an injectable colloidal cell delivery system. J. Colloid Interface Sci. 2010, 344:61-69.
208. Lee J.W., Lim T.H., Park J.B. Intradiscal drug delivery system for the treatment of low back pain. J. Biomed. Mater. Res. A 2009, 92:378-385.
209. Shimer A.L., Chadderdon R.C., Gilbertson L.G., Kang J.D. Gene therapy approaches for intervertebral disc degeneration. Spine (Phila Pa 1976) 2004, 29:2770-2778.
210. Sobajima S., Kim J.S., Gilbertson L.G., Kang J.D. Gene therapy for degenerative disc disease. Gene Ther. 2004, 11:390-401.
211. Robbins P.D., Ghivizzani S.C. Viral vectors for gene therapy. Pharmacol. Ther. 1998, 80:35-47.
212. He T.C., Zhou S.B., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:2509-2514.
213. Nishida K., Kang J.D., Gilbertson L.G., Moon S.H., Suh J.K., Vogt M.T., Robbins P.D., Evans C.H. Modulation of the biologic activity of the rabbit intervertebral disc by gene therapy: an in vivo study of adenovirus-mediated transfer of the human transforming growth factor beta 1 encoding gene. Spine (Phila Pa 1976) 1999, 24:2419-2425.
214. Wang H., Kroeber M., Hanke M., Ries R., Schmid C., Poller W., Richter W. Release of active and depot GDF-5 after adenovirus-mediated overexpression stimulates rabbit and human intervertebral disc cells. J. Mol. Med. 2004, 82:126-134.
215. Cui M., Wan Y., Anderson D.G., Shen F.H., Leo B.M., Laurencin C.T., Balian G., Li X. Mouse growth and differentiation factor-5 protein and DNA therapy potentiates intervertebral disc cell aggregation and chondrogenic gene expression. Spine J. 2008, 8:287-295.
216. Liang H.X., Ma S.Y., Feng G., Shen F.H., Li X.J. Therapeutic effects of adenovirus-mediated growth and differentiation factor-5 in a mice disc degeneration model induced by annulus needle puncture. Spine J. 2010, 10:32-41.
217. Zhang Y., Phillips F.M., Thonar E.J.M.A., Oegema T., An H.S., Roman-Blas J.A., He T.C., Anderson D.G. Cell therapy using articular chondrocytes overexpressing BMP-7 or BMP-10 in a rabbit disc organ culture model. Spine (Phila Pa 1976) 2008, 33:831-838.
218. Zhang Y.J., Li Z., Thonar E.J.M.A., An H.S., He T.C., Pietryla D., Phillips F.M. Transduced bovine articular chondrocytes affect the metabolism of cocultured nucleus pulposus cells in vitro: implications for chondrocyte transplantation into the intervertebral disc. Spine (Phila Pa 1976) 2005, 30:2601-2607.
219. Zhang Y.J., Markova D., Im H.J., Hu W.Y., Thonar E.J.M.A., He T.C., An H.S., Phillips F.M., Anderson D.G. Primary bovine intervertebral disc cells transduced with adenovirus overexpressing 12 B.P. and Sox9 maintain appropriate phenotype. Am. J. Phys. Med. Rehabil. 2009, 88:455-463.
220. Douglas J.T. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007, 36:71-80.
221. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 1996, 2:545-550.
222. Lattermann C., Oxner W.M., Xiao X., Li J., Gilbertson L.G., Robbins P.D., Kang J.D. The adeno associated viral vector as a strategy for intradiscal gene transfer in immune competent and pre-exposed rabbits. Spine (Phila Pa 1976) 2005, 30:497-504.
223. Sowa G., Westrick E., Pacek C., Coelho P., Patel D., Vadala G., Georgescu H., Vo N., Studer R., Kang J. In vitro and in vivo testing of a novel regulatory system for gene therapy for intervertebral disc degeneration. Spine (Phila Pa 1976) 2011, 36:E623-E628.
224. Wang C.F., Ruan D.K., Zhang C., Wang D.L., Xin H.K., Zhang Y. Effects of adeno-associated virus-2-mediated human BMP-7 gene transfection on the phenotype of nucleus pulposus cells. J. Orthop. Res. 2011, 29:838-845.
225. Paul R., Haydon R.C., Cheng H.W., Ishikawa A., Nenadovich N., Jiang W., Zhou L., Breyer B., Feng T., Gupta P., He T.C., Phillips F.M. Potential use of Sox9 gene therapy for intervertebral degenerative disc disease. Spine (Phila Pa 1976) 2003, 28:755-763.
226. Yoon S.T., Park J.S., Kim K.S., Li J., Attallah-Wasif E.S., Hutton W.C., Boden S.D. ISSLS prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and BMPs in vitro and in vivo. Spine (Phila Pa 1976) 2004, 29:2603-2611.
227. Boden S.D., Titus L., Hair G., Liu Y.S., Viggeswarapu M., Nanes M.S., Baranowski C. 1998 Volvo Award winner in basic science studies - lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive protein (LMP-1). Spine (Phila Pa 1976) 1998, 23:2486-2492.
228. Le Maitre C.L., Freemont A.J., Hoyland J.A. A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration. Int. J. Exp. Pathol. 2006, 87:17-28.
229. Wehling P., Schulitz K.P., Robbins P.D., Evans C.H., Reinecke J.A. Transfer of genes to chondrocytic cells of the lumbar spine - proposal for a treatment strategy of spinal disorders by local gene therapy. Spine (Phila Pa 1976) 1997, 22:1092-1097.
230. Wallach C.J., Sobajima S., Watanabe Y., Kim J.S., Georgescu H.I., Robbins P., Gilbertson L.G., Kang J.D. Gene transfer of the catabolic inhibitor TIMP-1 increases measured proteoglycans in cells from degenerated human intervertebral discs. Spine (Phila Pa 1976) 2003, 28:2331-2337.
231. Brown M.D., Schatzlein A.G., Uchegbu I.F. Gene delivery with synthetic (nonviral) carriers. Int. J. Pharm. 2001, 229:1-21.
232. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem. Rev. 2009, 109:259-302.
233. Oku N., Yamazaki Y., Matsuura M., Sugiyama M., Hasegawa M., Nango M. A novel non-viral gene transfer system, polycation liposomes. Adv. Drug Deliv. Rev. 2001, 52:209-218.
234. Luten J., van Nostruin C.F., De Smedt S.C., Hennink W.E. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J. Control. Release 2008, 126:97-110.
235. Canine B.F., Hatefi A. Development of recombinant cationic polymers for gene therapy research. Adv. Drug Deliv. Rev. 2010, 62:1524-1529.
236. Herweijer H., Wolff J.A. Progress and prospects: naked DNA gene transfer and therapy. Gene Ther. 2003, 10:453-458.
237. Chung S.A., Wei A.Q., Connor D.E., Webb G.C., Molloy T., Pajic M., Diwan A.D. Nucleus pulposus cellular longevity by telomerase gene therapy. Spine (Phila Pa 1976) 2007, 32:1188-1196.
238. Morrey M.E., Anderson P.A., Chambers G., Paul R. Optimizing nonviral-mediated transfection of human intervertebral disc chondrocytes. Spine J. 2008, 8:796-803.
239. Nishida K., Doita M., Takada T., Kakutani K., Miyamoto H., Shimomura T., Maeno K., Kurosaka M. Sustained transgene expression in intervertebral disc cells in vivo mediated by microbubble-enhanced ultrasound gene therapy. Spine (Phila Pa 1976) 2006, 31:1415-1419.
240. Geers B., Dewitte H., De Smedt S.C., Lentacker I. Crucial factors and emerging concepts in ultrasound-triggered drug delivery. J. Control. Release 2012, 164:248-255.
241. Dijkmans P.A., Juffermans L.J., Musters R.J., van Wamel A., ten Cate F.J., van Gilst W., Visser C.A., de Jong N., Kamp O. Microbubbles and ultrasound: from diagnosis to therapy. Eur. J. Echocardiogr. 2004, 5:245-256.
242. Kakutani K., Nishida K., Uno K., Takada T., Shimomura T., Maeno K., Kurosaka M., Doita M. Prolonged down regulation of specific gene expression in nucleus pulposus cell mediated by RNA interference in vitro. J. Orthop. Res. 2006, 24:1271-1278.
243. Suzuki T., Nishida K., Kakutani K., Maeno K., Yurube T., Takada T., Kurosaka M., Doita M. Sustained long-term RNA interference in nucleus pulposus cells in vivo mediated by unmodified small interfering RNA. Eur. Spine J. 2009, 18:263-270.
244. Seki S., Asanuma-Abe Y., Masuda K., Kawaguchi Y., Asanuma K., Muehleman C., Iwai A., Kimura T. Effect of small interference RNA (siRNA) for ADAMTS5 on intervertebral disc degeneration in the rabbit annular needle-puncture model. Arthritis Res. Ther. 2009, 11:R166.
245. Han D.F., Ding Y., Liu S.L., Wang G., Si I.C., Wang X.G., Cui L.Y., Huang D.S. Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro. Acta Biochim. Biophys. Sin. 2009, 41:938-947.
246. Sudo H., Minami A. Caspase 3 as a therapeutic target for regulation of intervertebral disc degeneration in rabbits. Arthritis Rheum. US 2011, 63:1648-1657.